fredrik

Trevor Archer and Thomas Lenz, has participated in the 30th annual which took place this year in Stockholm November 4-6. BIO-Europé is one of the top pharma events in Europe. The BIO-Europe program explores the impact of the Swedish approach, embodied by an openness to collaboration, has had on biotech innovation, and addresses the latest trends, challenges and opportunities in life science. Milmed received a lot of positive interest in its new patented longevity/antiaging product.… Read More »30th annual BIO-Europe

Milmed Unico’s new subsidiary Longevience AB is registred the 11th of October. Everything related to longevity and antiaging will be in our new company.

The 18th of June Milmed Unico AB submitted a new patent application, ”YEAST FOR PROMOTING LONGEVITY AND/OR ANTIAGING”. We believe that there are good conditions now to get this application approved, because the patent have very strong scientic results from our antiaging studies. There is both in vivo and in vitro studies performed at Sapienza university showing clear and positive effects on six main hallmarks for longevity and antiaging. This patent application is very important… Read More »New patent application submitted

Trevor Archer and Thomas Lenz participated in the 6th Biotech-Hanse Forum At the event, Trevor presented our latest research conducted at Sapienza University. The Biotech Hanse Forum assembles key players and emerging companies from the Swedish and German (language region) Pharma and Biotech Industry and provides a unique opportunity to present to a selected audience.

The future of Microbiome-based Medicinal Products Milmed Unico AB’s CEO, Thomas Lenz, has participated in the Pharmabiotics Conference in Lyon 21-22 March 2023:  “The Future of Microbiome-based Medicinal Products”. Pharmabiotic Research Institute (PRI) | European Microbiome Regulatory Science Center hosted the 8th annual 2023 Pharmabiotics Conference in Lyon, France. The conference bring in scientific and industry presentations which touch on nearly every aspect of a microbiome-based health product’s path to market, from fundamental and discovery/pre-clinical… Read More »Pharmabiotics Conference in Lyon 21-22 March 2023

Milmed Unico AB has recently received a positive statement from the International Patent Office in the examination of patent application no. PCT/SE2022/050656, YEAST FOR THE TREATMENT OF INFLAMMATION. The international authority makes an assessment as to whether the invention is patentable based on the submitted claims. The reviewer means that claim 3 ( … wherein the inflammation is inflammatory bowel disease (IBD), such as Crohn’s disease or ulcerative colitis; or irritable bowel syndrome (IBS) meets the… Read More »Patent approval – Inflammatory diseases

Milmed Unico AB’s CEO, Thomas Lenz, has participated in BIO-Europe’s conference in Leipzig together with 2,200 companies and over 4,000 representatives. Thomas had around 15 booked meetings with American, Canadian, Asian and European companies. Preferably with international investors but also with interesting future collaboration partners. The discussions will continue in several areas in the coming weeks.

We are proud to present our new board member in Milmed Unico AB, Anna Linton. Anna has over 20 years of experience from the development, commercialization and distribution of pharmaceuticals. During the last 10 years, she has been responsible for a life science company in an expansive phase. Experiences that are significant for Milmed Unico AB in our ambition to create non-toxic treatments without adverse side effects. Anna has recently joined Pharmiva as new CEO,… Read More »Milmed Unico broadens its competence with Anna Linton

Recently published article regarding inflammatory diseases, click on the headline to see the link to the article itself; Anti-inflammatory Action of the Treated-Yeast, Milmed, Under IBS-IBD Conditions aug 2022

29th of June Milmed Unico AB submitted another patent application and it concerns an international application for the treatment of inflammatory diseases. It is not simple to get a full patent application in order and also get it approved. We believe that there are good conditions now to get this application approved, which is very important for the future of the company holding even stronger intellectual property rights.